Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors

BACKGROUND: Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Darden, Christina, Price, Mark, Ray, David, Goldstein, Grace, Goss, Diana, Bennett, Lee, Garbinsky, Diana, Thota, Ramya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423948/
https://www.ncbi.nlm.nih.gov/pubmed/34491454
http://dx.doi.org/10.1186/s41687-021-00355-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423948/
https://www.ncbi.nlm.nih.gov/pubmed/34491454
http://dx.doi.org/10.1186/s41687-021-00355-5

Ejemplares similares